{"blog": [], "keywords": [{"value": "Drugs (Pharmaceuticals)", "name": "subject", "rank": "1", "is_major": "Y"}, {"value": "Mental Health and Disorders", "name": "subject", "rank": "2", "is_major": "Y"}, {"value": "AstraZeneca PLC", "name": "organizations", "rank": "3", "is_major": "Y"}, {"value": "Schulz, S Charles", "name": "persons", "rank": "4", "is_major": "Y"}, {"value": "Research", "name": "subject", "rank": "5", "is_major": "N"}, {"value": "Colleges and Universities", "name": "subject", "rank": "6", "is_major": "Y"}, {"value": "Clinical Trials", "name": "subject", "rank": "7", "is_major": "N"}, {"value": "University of Minnesota", "name": "organizations", "rank": "8", "is_major": "Y"}], "web_url": "http://www.nytimes.com/2015/04/19/business/seroquel-xr-drug-trial-frayed-promise.html", "document_type": "article", "byline": {"person": [{"lastname": "THOMAS", "firstname": "Katie", "role": "reported", "organization": "", "rank": 1}], "original": "By KATIE THOMAS", "contributor": "Jack Begg and Christina Capecchi contributed reporting."}, "type_of_material": "News", "multimedia": [{"url": "images/2015/04/19/business/19DRUGTRIALJP1/19DRUGTRIALJP1-thumbWide-v2.jpg", "legacy": {"wide": "images/2015/04/19/business/19DRUGTRIALJP1/19DRUGTRIALJP1-thumbWide-v2.jpg", "wideheight": "126", "widewidth": "190"}, "subtype": "wide", "type": "image", "width": 190, "height": 126}, {"url": "images/2015/04/19/business/19DRUGTRIALJP1/19-DRUGTRIAL-JP1-articleLarge.jpg", "legacy": {"xlarge": "images/2015/04/19/business/19DRUGTRIALJP1/19-DRUGTRIAL-JP1-articleLarge.jpg", "xlargeheight": "419", "xlargewidth": "600"}, "subtype": "xlarge", "type": "image", "width": 600, "height": 419}, {"url": "images/2015/04/19/business/19DRUGTRIALJP1/19DRUGTRIALJP1-thumbStandard-v2.jpg", "legacy": {"thumbnail": "images/2015/04/19/business/19DRUGTRIALJP1/19DRUGTRIALJP1-thumbStandard-v2.jpg", "thumbnailheight": "75", "thumbnailwidth": "75"}, "subtype": "thumbnail", "type": "image", "width": 75, "height": 75}], "section_name": "Business Day", "word_count": "2456", "source": "The New York Times", "subsection_name": null, "lead_paragraph": "A study of the drug Seroquel XR for patients with borderline personality disorder exposes the tangled mess of interests for academics and universities involved in clinical trials.", "pub_date": "2015-04-19T00:00:00Z", "news_desk": "SundayBusiness", "headline": {"print_headline": "A Drug Trial\u2019s Frayed Promise", "main": "A Drug Trial&#8217;s Frayed Promise"}, "print_page": "1", "snippet": "A study of the drug Seroquel XR for patients with borderline personality disorder exposes the tangled mess of interests for academics and universities involved in clinical trials.", "_id": "5531430b38f0d86ab80c21ea", "slideshow_credits": null, "abstract": "Deeply flawed study of anti-psychotic drug Seroquel XR, which initially offered new hope for treating borderline personality disorder, reveals how conflicts of interest among academics and universities can result in messy research; study was financed by AstraZeneca, which manufactures Seroquel, and was overseen by Dr S Charles Schulz, head of psychiatry at Univ of Minnesota with strong ties to pharmaceutical industry."}